Strucutre-Function claims are possible regarding internal natural GLP-1 production, but advice is to proceed with caution
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet
For reference on class-related adverse effects and warnings, the Summary of Product Characteristics (SmPC) for approved GLP-1 and dual GIP/GLP-1 receptor agonists including Wegovy (semaglutide) and Mounjaro (tirzepatide) are available on the Electronic Medicines Compendium (www.medicines.org.uk/emc)
Energy expenditure research has documented increases in metabolic rate markers in pre-clinical models treated with Retatrutide, with studies attributing this in part to the glucagon receptor component
Most individuals see the most dramatic changes over three to six months of use, along with healthy lifestyle modifications
This program is designed for lawful laboratory developmental research use only with terms of sale that support non clinical bench workflows
